Monthly Archives: April 2021

The FDA has granted accelerated approval to sacituzumab govitecan (Trodelvy) to treat patients with locally advanced or metastatic urothelial carcinoma after having received a PD-1 / PD-L1 inhibitor and platinum-based chemotherapy This is based on the results of the phase 2 TROPHY-U-01 trial. This approval makes sacituzumab govitecan the first drug with a third-line indication […]

This pilot clinical feasibility study was recently published in the International Journal of Clinical Practices by a Turkish Group from the Ataturk University School of Medicine, Erzurum, Turkey. Note that this is yet a standard practice, and currently a pilot feasibility study. We have to await for more studies, but it does seem promising for […]

Tivozanib (Fotivda) has been added to the National Comprehensive Cancer Network (NCCN) guidelines for use as a subsequent therapy following first-line treatment recommendations for patients with clear cell renal cell carcinoma (RCC), according to AVEO Oncology, the developer of the oral, next-generation VEGF tyrosine kinase inhibitor. The FDA approved tivozanib on March 10, 2021, for […]

Increasing fluid intake and making dietary lifestyle changes can prevent future stones or at least reduce the incidence of kidney stone disease. High fluids intake is the most important factor for preventing kidney stone disease and for every 200 mL of water, the risk of stones is reduced by 13%. From the National Kidney Foundation; […]

The FDA approved the angiogenesis inhibitor tivozanib (Fotivda) for relapsed/refractory advanced renal cell carcinoma (RCC). Tivozanib is now the first approved therapy for patients who received two or more prior lines of therapy for advanced RCC. Support for the approval came primarily from the randomized TIVO-3 trial that showed tivozanib improved progression-free survival (PFS) as […]

The U.S. Food and Drug Administration on 25th March 2021 approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older. Myrbetriq (mirabegron extended-release tablets) is now approved for […]